Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 8/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386707 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL21286125 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL1241324 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL1241323 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL19964151 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL142689 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL20312947 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL1372634 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL30868937 | 0.97 | NR1H2 (0.40) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL6577745 | 0.92 | NR1H2 (0.41) | NR1H2SRCMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3853234-B1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-112996795-B | Fused tricyclic derivatives as SRC homo-2 phosphatase inhibitors | 尼坎治疗公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-113227103-B | Trisubstituted heteroaryl derivatives as SRC homo-2 phosphatase inhibitors | 尼坎治疗公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-113072542-B | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20200115389-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| WO-2020061103-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| EP-2889287-B1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING SAME AND ANTICANCER DRUG COMPOSITION CONTAINING SAME | CELLTRION INC (KR) | 2016-08-31 | — | — | EP | disclosed |
| US-9278996-B2 | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same | CELLTRION, INC. (KR) | 2016-03-08 | — | — | US | disclosed |
| US-20150225455-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME | CELLTRION, INC. (KR) | 2015-08-13 | — | — | US | disclosed |
| EP-2889287-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING SAME AND ANTICANCER DRUG COMPOSITION CONTAINING SAME | Celltrion, Inc. (KR) | 2015-07-01 | — | — | EP | disclosed |
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-1905759-A1 | N-[1-(3-AMINO-4-PHENYL-BUTYRYL)-4-HYDROXY-PYRROLIDIN-2-YLMETHYL}-PROPIONAMIDE AND RELATED COMPOUNDS AS DPP-IV INHIBITORS FOR THE TREATMENT OFTYPE 2 DIABETES MELLITUS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008028662-A1 | N-[1-(3-AMINO-4-PHENYL-BUTYRYL)-4-HYDROXY-PYRROLIDIN-2-YLMETHYL}-PROPIONAMIDE AND RELATED COMPOUNDS AS DPP-IV INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225455-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME | DAD1, DDOST, SCD5 | NR1H2 258/4885SRC 3232/4885ABCB1 259/4885 |
| US-20200115389-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | SRC, PTPRCAP, PTPRC | NR1H2 1674/4885SRC 1/4885ABCB1 2588/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1539/4885SRC 628/4885ABCB1 797/4885 |
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | RECQL, BLVRB, NQO2 | NR1H2 971/4885SRC 4616/4885ABCB1 53/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | NR1H2 2769/4885SRC 1461/4885ABCB1 383/4885 |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | NR1H2 2154/4885SRC 1/4885ABCB1 2553/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | NR1H2 2872/4885SRC 665/4885ABCB1 564/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | NR1H2 2769/4885SRC 1461/4885ABCB1 383/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1539/4885SRC 628/4885ABCB1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.